This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.

Click here and I’ll tell you everything you need to know.

Dirk Kersten Biography and Net Worth

Director of Dyne Therapeutics

Dirk is a general partner at Forbion, a leading European life science venture capital firm, where he focuses primarily on new investments. He is a physicist by training and previously was a partner at Gilde Healthcare Partners, where he led U.S. operations. Previously, Dirk was a managing director at INKEF Capital, where he was responsible for all healthcare investment activities. Dirk led a series of investments in Europe and the U.S. and is an active board member at a number of life science companies, including NorthSea Therapeutics B.V. and Synox Therapeutics Limited. Previously, Dirk served on the board of directors at Ascendis Pharma, Lanthio Pharma (acquired by Morphosys), Profibrix (acquired by The Medicines Company) and Nightbalance (acquired by Royal Philips).

Dirk received his M.S. in physics from the University of Groningen in the Netherlands.

What is Dirk Kersten's net worth?: The estimated net worth of Dirk Kersten is at least $2.99 million as of October 16th, 2024. Mr. Kersten owns 99,652 shares of Dyne Therapeutics stock worth more than $2,988,563 as of November 21st. This net worth approximation does not reflect any other assets that Mr. Kersten may own. Learn More about Dirk Kersten's net worth.
How do I contact Dirk Kersten?: The corporate mailing address for Mr. Kersten and other Dyne Therapeutics executives is 1560 Trapelo Road, Waltham, MA 02451, United States. Dyne Therapeutics can also be reached via phone at 781-786-8230 and via email at [email protected]. Learn More on Dirk Kersten's contact information.
Has Dirk Kersten been buying or selling shares of Dyne Therapeutics?: During the past quarter, Dirk Kersten has sold $836,769.85 in shares of Dyne Therapeutics stock. Most recently, Dirk Kersten sold 23,671 shares of the business's stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $35.35, for a transaction totalling $836,769.85. Following the completion of the sale, the director now directly owns 99,652 shares of the company's stock, valued at $3,522,698.20. Learn More on Dirk Kersten's trading history.
Who are Dyne Therapeutics' active insiders?: Dyne Therapeutics' insider roster includes Oxana Beskrovnaya (Chief Scientific Officer), Joshua Brumm (CEO), John Cox (President & CEO), Wildon Farwell (Insider), Susanna High (COO), Dirk Kersten (Director), and Richard Scalzo (Insider). Learn More on Dyne Therapeutics' active insiders.
Are insiders buying or selling shares of Dyne Therapeutics?: During the last year, Dyne Therapeutics insiders bought shares 2 times. They purchased a total of 1,746,285 shares worth more than $31,057,267.50. During the last year, insiders at the sold shares 51 times. They sold a total of 2,551,709 shares worth more than $62,622,812.31. The most recent insider tranaction occured on November, 18th when Director Carlo Incerti sold 16,500 shares worth more than $474,045.00. Insiders at Dyne Therapeutics own 20.8% of the company. Learn More about insider trades at Dyne Therapeutics.
Information on this page was last updated on 11/18/2024.

Dirk Kersten Insider Trading History at Dyne Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/16/2024	Sell	23,671	$35.35	$836,769.85	99,652
9/25/2024	Sell	2,357	$35.06	$82,636.42	190,939
9/23/2024	Sell	40,831	$35.32	$1,442,150.92	193,296
9/20/2024	Sell	79,411	$36.45	$2,894,530.95	234,127
1/9/2024	Buy	1,714,285	$17.50	$29,999,987.50	6,416,793

Dirk Kersten Buying and Selling Activity at Dyne Therapeutics

Dyne Therapeutics Company Overview

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $29.99

$28.68

$30.28

50 Day Range

MA: $32.31

$28.13

$36.59

2 Week Range

Now: $29.99

$10.03

$47.45

Volume

1,087,662 shs

Average Volume

1,086,944 shs

Market Capitalization

$3.05 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

Missed Nvidia? Watch this ASAP

From Brownstone Research | Ad